PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Naltrexone hydrochloride - Multiple sclerosis
PAD Profile : Naltrexone hydrochloride - Multiple sclerosis
Keywords :
MS, low dose naltrexone
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Fampridine
- Fingolimod
- Glatiramer acetate
- Interferon beta
- Teriflunomide
- Modafinil
- Cladribine
- Ocrelizumab
- Biotin
- Ponesimod
- Ozanimod
- Peginterferon beta-1a
- Memantine hydrochloride
- Donepezil hydrochloride
- Galantamine
- Rivastigmine
- Diroximal fumarate
- Alemtuzumab
- Dimethyl fumarate
- Natalizumab
- Ofatumumab
- Siponimod
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
04 June 2010
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The APC committee did not support the use of low dose naltrexone for MS and agreed that this would be added to NHS Surrey's Low Priority Procedure list as something that is not routinely funded.
Associated BNF Codes
01. Gastro-Intestinal System
01.06.06. Peripheral opioid-receptor antagonists